© 1998 by Oxford University Press
Journal Of The National Cancer Institute, Vol 90, 455-460, Copyright © 1998 by Oxford University Press
D Hwang, D Scollard, J Byrne and E Levine
BACKGROUND: Numerous studies have demonstrated that the levels of
prostaglandins are greater in various cancers, including breast cancer and
colon cancer, than in normal tissues. In particular, the inducible form of
cyclooxygenase (COX), the rate-limiting enzyme in prostaglandin
biosynthesis, is overexpressed in colon tumors. Epidemiologic studies have
demonstrated that the use of aspirin or other nonsteroidal anti-
inflammatory drugs (NSAIDs) can reduce the risk of colon cancer and, to a
lesser extent, the risk of breast cancer. NSAIDs are known to inhibit COX,
suggesting that the beneficial effect of NSAIDs in colon cancer may be
related to COX overexpression in this disease. This possibility led us to
ask whether COX is also overexpressed in breast cancers. METHODS: Surgical
specimens from 44 patients with breast cancer who had undergone lumpectomy
or mastectomy were analyzed by immunoblot analysis and immunohistochemical
analysis to determine the expression profile of the constitutively
expressed form of cyclooxygenase (COX-1) and the inducible form (COX-2);
the specimens from 14 patients included normal breast tissue. RESULTS:
Expression of COX-1 protein was substantially higher in 30 of 44 tumor
samples than in any of the 14 normal tissue specimens. Immunoblot analysis
revealed extremely high levels of COX-2 protein in two tumor samples.
Immunohistochemical staining of specimens that expressed COX-1 and/or COX-2
revealed that COX-1 was localized in stromal cells adjacent to the tumor
but not in tumor cells. In contrast, COX-2 was localized primarily in tumor
cells but also appeared in stromal cells. CONCLUSION: Our results suggest
that overexpression of COX may not be unique to colon cancer and may be a
feature common to other epithelial tumors.
ARTICLES
Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer
Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA. hwangdh@mhs.pbrc.edu
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. Sirianni, A. Chimento, A. De Luca, F. Zolea, A. Carpino, V. Rago, M. Maggiolini, S. Ando, and V. Pezzi Inhibition of Cyclooxygenase-2 Down-regulates Aromatase Activity and Decreases Proliferation of Leydig Tumor Cells J. Biol. Chem., October 16, 2009; 284(42): 28905 - 28916. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sahin, E. Sahin, and S. Gumuslu Cyclooxygenase-2 in Cancer and Angiogenesis Angiology, April 1, 2009; 60(2): 242 - 253. [Abstract] [PDF] |
||||
![]() |
C. Falandry, P. A. Canney, G. Freyer, and L. Y. Dirix Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer Ann. Onc., April 1, 2009; 20(4): 615 - 620. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Takkouche, C. Regueira-Mendez, and M. Etminan Breast Cancer and Use of Nonsteroidal Anti-inflammatory Drugs: A Meta-analysis J Natl Cancer Inst, October 15, 2008; 100(20): 1439 - 1447. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F Dillon, A. T Stafford, G. Kelly, A. M Redmond, M. McIlroy, T. B Crotty, E McDermott, A. D Hill, and L. S Young Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients Endocr. Relat. Cancer, September 1, 2008; 15(3): 745 - 753. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Moysich, G. P. Beehler, G. Zirpoli, J.-Y. Choi, and J. A. Baker Use of Common Medications and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1564 - 1595. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Molloy, M. P. Morgan, G. A. Doherty, B. McDonnell, M. Hilliard, J. O'Byrne, D. J. Fitzgerald, and G. M. McCarthy Mechanism of basic calcium phosphate crystal-stimulated cyclo-oxygenase-1 up-regulation in osteoarthritic synovial fibroblasts Rheumatology, July 1, 2008; 47(7): 965 - 971. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-R. Pan, M.-F. Hou, H.-C. Chang, and W.-C. Hung Cyclooxygenase-2 Up-regulates CCR7 via EP2/EP4 Receptor Signaling Pathways to Enhance Lymphatic Invasion of Breast Cancer Cells J. Biol. Chem., April 25, 2008; 283(17): 11155 - 11163. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhao, M. Goswami, N. Pokhriyal, H. Ma, H. Du, J. Yao, T. A. Victor, K. Polyak, C. D. Sturgis, H. Band, et al. Cyclooxygenase-2 Expression during Immortalization and Breast Cancer Progression Cancer Res., January 15, 2008; 68(2): 467 - 475. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hall-Pogar, S. Liang, L. K. Hague, and C. S. Lutz Specific trans-acting proteins interact with auxiliary RNA polyadenylation elements in the COX-2 3'-UTR RNA, July 1, 2007; 13(7): 1103 - 1115. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Battersby, K.J. Sales, A.R. Williams, R.A. Anderson, S. Gardner, and H.N. Jabbour Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway Hum. Reprod., January 1, 2007; 22(1): 36 - 44. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jimeno, M. L. Amador, P. Kulesza, X. Wang, B. Rubio-Viqueira, X. Zhang, A. Chan, J. Wheelhouse, H. Kuramochi, K. Tanaka, et al. Assessment of celecoxib pharmacodynamics in pancreatic cancer Mol. Cancer Ther., December 1, 2006; 5(12): 3240 - 3247. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Jayaprakash, N. R. Rigual, K. B. Moysich, T. R. Loree, M. A. S. Nasca, R. J. Menezes, and M. E. Reid Chemoprevention of head and neck cancer with aspirin: a case-control study. Arch Otolaryngol Head Neck Surg, November 1, 2006; 132(11): 1231 - 1236. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lanza-Jacoby, R. Burd, F. E. Rosato Jr., K. McGuire, J. Little, N. Nougbilly, and S. Miller Effect of Simultaneous Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in HER-2/Neu-Positive Breast Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6161 - 6169. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Brunelle, E. A. Sartin, L. G. Wolfe, J. Sirois, and M. Dore Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines. Vet. Pathol., September 1, 2006; 43(5): 656 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
K J Schmitz, R Callies, J Wohlschlaeger, R Kimmig, F Otterbach, J Bohr, H-S Lee, A Takeda, K W Schmid, and H A Baba Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways J. Clin. Pathol., July 1, 2006; 59(7): 685 - 691. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Subbaramaiah, L. R. Howe, E. R. Port, E. Brogi, J. Fishman, C. H. Liu, T. Hla, C. Hudis, and A. J. Dannenberg HER-2/neu Status Is a Determinant of Mammary Aromatase Activity In vivo: Evidence for a Cyclooxygenase-2-Dependent Mechanism. Cancer Res., May 15, 2006; 66(10): 5504 - 5511. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lu, W. Ouyang, and C. Huang Inflammation, a Key Event in Cancer Development Mol. Cancer Res., April 1, 2006; 4(4): 221 - 233. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Naruse, Y. Nishida, K. Hosono, and N. Ishiguro Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes Carcinogenesis, March 1, 2006; 27(3): 584 - 592. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kaul, S. C. Verma, M. Murakami, K. Lan, T. Choudhuri, and E. S. Robertson Epstein-Barr Virus Protein Can Upregulate Cyclo-Oxygenase-2 Expression through Association with the Suppressor of Metastasis Nm23-H1 J. Virol., February 1, 2006; 80(3): 1321 - 1331. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Secchiero, E. Barbarotto, A. Gonelli, M. Tiribelli, C. Zerbinati, C. Celeghini, C. Agostinelli, S. A. Pileri, and G. Zauli Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells Am. J. Pathol., December 1, 2005; 167(6): 1599 - 1607. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. N. Jabbour, K. J. Sales, S. C. Boddy, R. A. Anderson, and A. R. W. Williams A Positive Feedback Loop that Regulates Cyclooxygenase-2 Expression and Prostaglandin F2{alpha} Synthesis via the F-Series-Prostanoid Receptor and Extracellular Signal-Regulated Kinase 1/2 Signaling Pathway Endocrinology, November 1, 2005; 146(11): 4657 - 4664. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Stoner, H. Qin, T. Chen, P. S. Carlton, M. E. Rose, R. M. Aziz, and R. Dixit The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis Carcinogenesis, September 1, 2005; 26(9): 1590 - 1595. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Cook, I-M. Lee, J. M. Gaziano, D. Gordon, P. M Ridker, J. E. Manson, C. H. Hennekens, and J. E. Buring Low-Dose Aspirin in the Primary Prevention of Cancer: The Women's Health Study: A Randomized Controlled Trial JAMA, July 6, 2005; 294(1): 47 - 55. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Arun, G. Kilic, C. Yen, B. Foster, D. A. Yardley, R. Gaynor, and R. Ashfaq Loss of FHIT Expression in Breast Cancer Is Correlated with Poor Prognostic Markers Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1681 - 1685. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. H.A. von Rahden, H. J. Stein, F. Puhringer, I. Koch, R. Langer, G. Piontek, J. R. Siewert, H. Hofler, and M. Sarbia Coexpression of Cyclooxygenases (COX-1, COX-2) and Vascular Endothelial Growth Factors (VEGF-A, VEGF-C) in Esophageal Adenocarcinoma Cancer Res., June 15, 2005; 65(12): 5038 - 5044. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Santini, B. Vincenzi, G. Tonini, S. Scarpa, F. Vasaturo, C. Malacrino, F. Vecchio, D. Borzomati, S. Valeri, R. Coppola, et al. Cyclooxygenase-2 Overexpression Is Associated with a Poor Outcome in Resected Ampullary Cancer Patients Clin. Cancer Res., May 15, 2005; 11(10): 3784 - 3789. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hall-Pogar, H. Zhang, B. Tian, and C. S. Lutz Alternative polyadenylation of cyclooxygenase-2 Nucleic Acids Res., May 4, 2005; 33(8): 2565 - 2579. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Davis, M. T. McCabe, S. W. Hayward, J. M. Park, and M. L. Day Disruption of Rb/E2F Pathway Results in Increased Cyclooxygenase-2 Expression and Activity in Prostate Epithelial Cells Cancer Res., May 1, 2005; 65(9): 3633 - 3642. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Diaz-Cruz, C. L. Shapiro, and R. W. Brueggemeier Cyclooxygenase Inhibitors Suppress Aromatase Expression and Activity in Breast Cancer Cells J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2563 - 2570. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Uchida, S. Schneider, J. M. Yochim, H. Kuramochi, K. Hayashi, K. Takasaki, D. Yang, K. D. Danenberg, and P. V. Danenberg Intratumoral COX-2 Gene Expression Is a Predictive Factor for Colorectal Cancer Response to Fluoropyrimidine-Based Chemotherapy Clin. Cancer Res., May 1, 2005; 11(9): 3363 - 3368. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Kong, H.-T. Kim, K. Wu, D. DeNardo, S. G. Hilsenbeck, X.-C. Xu, W. W. Lamph, R. Bissonnette, A. J. Dannenberg, and P. H. Brown The Retinoid X Receptor-Selective Retinoid, LGD1069, Down-regulates Cyclooxygenase-2 Expression in Human Breast Cells through Transcription Factor Crosstalk: Implications for Molecular-Based Chemoprevention Cancer Res., April 15, 2005; 65(8): 3462 - 3469. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-Y. Lo, K.-Y. Lam, P. P Leung, and J. M Luk High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma Eur. J. Endocrinol., April 1, 2005; 152(4): 545 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Oyama, T. Fujimura, I. Ninomiya, T. Miyashita, S. Kinami, S. Fushida, T. Ohta, and M. Koichi A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats Carcinogenesis, March 1, 2005; 26(3): 565 - 570. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-P. Lin, S. K. Kulp, P.-H. Tseng, Y.-T. Yang, C.-C. Yang, C.-S. Chen, and C.-S. Chen Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms Mol. Cancer Ther., December 1, 2004; 3(12): 1671 - 1680. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Sauter, L. Schlatter, J. Hewett, D. Koivunen, and J. T. Flynn Lack of Effect of Celecoxib on Prostaglandin E2 Concentrations in Nipple Aspirate Fluid from Women at Increased Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1745 - 1750. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ito, M. Duxbury, E. Benoit, T. E. Clancy, M. J. Zinner, S. W. Ashley, and E. E. Whang Prostaglandin E2 Enhances Pancreatic Cancer Invasiveness through an Ets-1-Dependent Induction of Matrix Metalloproteinase-2 Cancer Res., October 15, 2004; 64(20): 7439 - 7446. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Quidville, N. Segond, E. Pidoux, R. Cohen, A. Jullienne, and S. Lausson Tumor Growth Inhibition by Indomethacin in a Mouse Model of Human Medullary Thyroid Cancer: Implication of Cyclooxygenases and 15-Hydroxyprostaglandin Dehydrogenase Endocrinology, May 1, 2004; 145(5): 2561 - 2571. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. W. Chang, D. H. Kim, D. P. Kowalski, J. A. Burleson, Y. H. Son, L. D. Wilson, and B. G. Haffty Prognostic Significance of Cyclooxygenase-2 in Oropharyngeal Squamous Cell Carcinoma Clin. Cancer Res., March 1, 2004; 10(5): 1678 - 1684. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Velicer, S. R. Heckbert, J. W. Lampe, J. D. Potter, C. A. Robertson, and S. H. Taplin Antibiotic Use in Relation to the Risk of Breast Cancer JAMA, February 18, 2004; 291(7): 827 - 835. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Ness and J. A. Cauley Antibiotics and Breast Cancer--What's the Meaning of This? JAMA, February 18, 2004; 291(7): 880 - 881. [Full Text] [PDF] |
||||
![]() |
S. K. Kulp, Y.-T. Yang, C.-C. Hung, K.-F. Chen, J.-P. Lai, P.-H. Tseng, J. W. Fowble, P. J. Ward, and C.-S. Chen 3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells Cancer Res., February 15, 2004; 64(4): 1444 - 1451. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Badawi, M. B. Eldeen, Y. Liu, E. A. Ross, and M. Z. Badr Inhibition of Rat Mammary Gland Carcinogenesis by Simultaneous Targeting of Cyclooxygenase-2 and Peroxisome Proliferator-activated Receptor {gamma} Cancer Res., February 1, 2004; 64(3): 1181 - 1189. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lanza-Jacoby, S. Miller, J. Flynn, K. Gallatig, C. Daskalakis, J. L. Masferrer, B. S. Zweifel, H. Sembhi, and I. H. Russo The Cyclooxygenase-2 Inhibitor, Celecoxib, Prevents the Development of Mammary Tumors in HER-2/neu Mice Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1486 - 1491. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. B. Perchick and H. N. Jabbour Cyclooxygenase-2 Overexpression Inhibits Cathepsin D-Mediated Cleavage of Plasminogen to the Potent Antiangiogenic Factor Angiostatin Endocrinology, December 1, 2003; 144(12): 5322 - 5328. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. Lee, J. Ye, Z. Gao, H. S. Youn, W. H. Lee, L. Zhao, N. Sizemore, and D. H. Hwang Reciprocal Modulation of Toll-like Receptor-4 Signaling Pathways Involving MyD88 and Phosphatidylinositol 3-Kinase/AKT by Saturated and Polyunsaturated Fatty Acids J. Biol. Chem., September 26, 2003; 278(39): 37041 - 37051. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-S. Herbert, V. P. Pearce, L. S. Hynan, D. M. LaRue, W. E. Wright, L. Kopelovich, and J. W. Shay A Peroxisome Proliferator-activated Receptor-{gamma} Agonist and the p53 Rescue Drug CP-31398 Inhibit the Spontaneous Immortalization of Breast Epithelial Cells Cancer Res., April 15, 2003; 63(8): 1914 - 1919. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. Lee, A. Plakidas, W. H. Lee, A. Heikkinen, P. Chanmugam, G. Bray, and D. H. Hwang Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids J. Lipid Res., March 1, 2003; 44(3): 479 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dore, I. Lanthier, and J. Sirois Cyclooxygenase-2 Expression in Canine Mammary Tumors Vet. Pathol., March 1, 2003; 40(2): 207 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bagga, L. Wang, R. Farias-Eisner, J. A. Glaspy, and S. T. Reddy Differential effects of prostaglandin derived from omega -6 and omega -3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion PNAS, February 18, 2003; 100(4): 1751 - 1756. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. W. Johnson, K. E. Anderson, D. Lazovich, and A. R. Folsom Association of Aspirin and Nonsteroidal Anti-inflammatory Drug Use with Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1586 - 1591. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Wu, H.S. Sun, C.-C. Lin, K.-Y. Hsiao, P.-C. Chuang, H.-A. Pan, and S.-J. Tsai Distinct mechanisms regulate cyclooxygenase-1 and -2 in peritoneal macrophages of women with and without endometriosis Mol. Hum. Reprod., December 1, 2002; 8(12): 1103 - 1110. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Hardman Omega-3 Fatty Acids to Augment Cancer Therapy J. Nutr., November 1, 2002; 132(11): 3508S - 3512. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ferrandina, L. Lauriola, G. F. Zannoni, A. Fagotti, F. Fanfani, F. Legge, N. Maggiano, M. Gessi, S. Mancuso, F. O. Ranelletti, et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients Ann. Onc., August 1, 2002; 13(8): 1205 - 1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Carlton, R. Gopalakrishnan, A. Gupta, B. W. Liston, S. Habib, M. A. Morse, and G. D. Stoner Piroxicam Is an Ineffective Inhibitor of N-Nitrosomethylbenzylamine-induced Tumorigenesis in the Rat Esophagus Cancer Res., August 1, 2002; 62(15): 4376 - 4382. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. F. Orengo, J. Gerguis, R. Phillips, A. Guevara, A. T. Lewis, and H. S. Black Celecoxib, a Cyclooxygenase 2 Inhibitor as a Potential Chemopreventive to UV-Induced Skin Cancer: A Study in the Hairless Mouse Model Arch Dermatol, June 1, 2002; 138(6): 751 - 755. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Costa, R Soares, J S Reis-Filho, D Leitao, I Amendoeira, and F C Schmitt Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer J. Clin. Pathol., June 1, 2002; 55(6): 429 - 434. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Edwards, S. P. Faux, S. M. Plummer, K. R. Abrams, R. A. Walker, D. A. Waller, and K. J. O'Byrne Cyclooxygenase-2 Expression Is a Novel Prognostic Factor in Malignant Mesothelioma Clin. Cancer Res., June 1, 2002; 8(6): 1857 - 1862. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Subbaramaiah, L. Norton, W. Gerald, and A. J. Dannenberg Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer. EVIDENCE FOR INVOLVEMENT OF AP-1 AND PEA3 J. Biol. Chem., May 17, 2002; 277(21): 18649 - 18657. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chu, S. Rushdi, E.T. Zumpe, P. Mamers, D.L. Healy, T. Jobling, H.G. Burger, and P.J. Fuller FSH-regulated gene expression profiles in ovarian tumours and normal ovaries Mol. Hum. Reprod., May 1, 2002; 8(5): 426 - 433. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Davies, L.-A. Martin, N. Sacks, and M. Dowsett Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention Ann. Onc., May 1, 2002; 13(5): 669 - 678. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Waskewich, R. D. Blumenthal, H. Li, R. Stein, D. M. Goldenberg, and J. Burton Celecoxib Exhibits the Greatest Potency amongst Cyclooxygenase (COX) Inhibitors for Growth Inhibition of COX-2-negative Hematopoietic and Epithelial Cell Lines Cancer Res., April 1, 2002; 62(7): 2029 - 2033. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kundu and A. M. Fulton Selective Cyclooxygenase (COX)-1 or COX-2 Inhibitors Control Metastatic Disease in a Murine Model of Breast Cancer Cancer Res., April 1, 2002; 62(8): 2343 - 2346. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Wallace Nutritional and Botanical Modulation of the Inflammatory Cascade--Eicosanoids, Cyclooxygenases, and Lipoxygenases-- As an Adjunct in Cancer Therapy Integr Cancer Ther, March 1, 2002; 1(1): 7 - 37. [Abstract] [PDF] |
||||
![]() |
E. Half, X. M. Tang, K. Gwyn, A. Sahin, K. Wathen, and F. A. Sinicrope Cyclooxygenase-2 Expression in Human Breast Cancers and Adjacent Ductal Carcinoma in Situ Cancer Res., March 1, 2002; 62(6): 1676 - 1681. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Niki, T. Kohno, S. Iba, Y. Moriya, Y. Takahashi, M. Saito, A. Maeshima, T. Yamada, Y. Matsuno, M. Fukayama, et al. Frequent Co-Localization of Cox-2 and Laminin-5 {gamma}2 Chain at the Invasive Front of Early-Stage Lung Adenocarcinomas Am. J. Pathol., March 1, 2002; 160(3): 1129 - 1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ferrandina, L. Lauriola, M. G. Distefano, G. F. Zannoni, M. Gessi, F. Legge, N. Maggiano, S. Mancuso, A. Capelli, G. Scambia, et al. Increased Cyclooxygenase-2 Expression Is Associated With Chemotherapy Resistance and Poor Survival in Cervical Cancer Patients J. Clin. Oncol., February 15, 2002; 20(4): 973 - 981. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ristimaki, A. Sivula, J. Lundin, M. Lundin, T. Salminen, C. Haglund, H. Joensuu, and J. Isola Prognostic Significance of Elevated Cyclooxygenase-2 Expression in Breast Cancer Cancer Res., February 1, 2002; 62(3): 632 - 635. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. TOSETTI, N. FERRARI, S. DE FLORA, and A. ALBINI Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents FASEB J, January 1, 2002; 16(1): 2 - 14. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Sales, A. A. Katz, B. Howard, R. P. Soeters, R. P. Millar, and H. N. Jabbour Cyclooxygenase-1 Is Up-Regulated in Cervical Carcinomas: Autocrine/Paracrine Regulation of Cyclooxygenase-2, Prostaglandin E Receptors, and Angiogenic Factors by Cyclooxygenase-1 Cancer Res., January 1, 2002; 62(2): 424 - 432. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zha, W. R. Gage, J. Sauvageot, E. A. Saria, M. J. Putzi, C. M. Ewing, D. A. Faith, W. G. Nelson, A. M. De Marzo, and W. B. Isaacs Cyclooxygenase-2 Is Up-Regulated in Proliferative Inflammatory Atrophy of the Prostate, but not in Prostate Carcinoma Cancer Res., December 1, 2001; 61(24): 8617 - 8623. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kawamori, N. Uchiya, S. Nakatsugi, K. Watanabe, S. Ohuchida, H. Yamamoto, T. Maruyama, K. Kondo, T. Sugimura, and K. Wakabayashi Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP1 antagonist, on breast cancer development Carcinogenesis, December 1, 2001; 22(12): 2001 - 2004. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. HWANG Modulation of the expression of cyclooxygenase-2 by fatty acids mediated through Toll-like receptor 4-derived signaling pathways FASEB J, December 1, 2001; 15(14): 2556 - 2564. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Fritsche, S. J. Baek, L. M. King, D. C. Zeldin, T. E. Eling, and D. A. Bell Functional Characterization of Cyclooxygenase-2 Polymorphisms J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 468 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Bing, M. Miyataka, K. A. Rich, N. Hanson, X. Wang, H. D. Slosser, and S.-R. Shi Nitric Oxide, Prostanoids, Cyclooxygenase, and Angiogenesis in Colon and Breast Cancer Clin. Cancer Res., November 1, 2001; 7(11): 3385 - 3392. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Klimp, H. Hollema, C. Kempinga, A. G. J. van der Zee, E. G. E. de Vries, and T. Daemen Expression of Cyclooxygenase-2 and Inducible Nitric Oxide Synthase in Human Ovarian Tumors and Tumor-associated Macrophages Cancer Res., October 1, 2001; 61(19): 7305 - 7309. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Blumenthal, C. Waskewich, D. M. Goldenberg, W. Lew, C. Flefleh, and J. Burton Chronotherapy and Chronotoxicity of the Cyclooxygenase-2 Inhibitor, Celecoxib, in Athymic Mice Bearing Human Breast Cancer Xenografts Clin. Cancer Res., October 1, 2001; 7(10): 3178 - 3185. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Murono, H. Inoue, T. Tanabe, I. Joab, T. Yoshizaki, M. Furukawa, and J. S. Pagano Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells PNAS, May 24, 2001; (2001) 121016998. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N. DuBois Cyclooxygenease-2 and Hepatocellular Carcinoma: Is It a Target for Prevention? Clin. Cancer Res., May 1, 2001; 7(5): 1110 - 1110. [Full Text] |
||||
![]() |
Z. Li, Y. Shimada, A. Kawabe, F. Sato, M. Maeda, I. Komoto, T. Hong, Y. Ding, J. Kaganoi, and M. Imamura Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor Carcinogenesis, April 1, 2001; 22(4): 547 - 551. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Subbarayan, A. L. Sabichi, N. Llansa, S. M. Lippman, and D. G. Menter Differential Expression of Cyclooxygenase-2 and Its Regulation by Tumor Necrosis Factor-{{alpha}} in Normal and Malignant Prostate Cells Cancer Res., March 1, 2001; 61(6): 2720 - 2726. [Abstract] [Full Text] |
||||
![]() |
S Chariyalertsak, V Sirikulchayanonta, D Mayer, A Kopp-Schneider, G Furstenberger, F Marks, and K Muller-Decker Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma Gut, January 1, 2001; 48(1): 80 - 86. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Grubbs, R. A. Lubet, A. T. Koki, K. M. Leahy, J. L. Masferrer, V. E. Steele, G. J. Kelloff, D. L. Hill, and K. Seibert Celecoxib Inhibits N-Butyl-N-(4-hydroxybutyl)-nitrosamine-induced Urinary Bladder Cancers in Male B6D2F1 Mice and Female Fischer-344 Rats Cancer Res., October 1, 2000; 60(20): 5599 - 5602. [Abstract] [Full Text] |
||||
![]() |
M. G. Malkowski, S. L. Ginell, W. L. Smith, and R. M. Garavito The Productive Conformation of Arachidonic Acid Bound to Prostaglandin Synthase Science, September 15, 2000; 289(5486): 1933 - 1937. [Abstract] [Full Text] |
||||
![]() |
N. Rioux and A. Castonguay The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-{kappa}B Carcinogenesis, September 1, 2000; 21(9): 1745 - 1751. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Williams and D. H. Phillips Mammary Expression of Xenobiotic Metabolizing Enzymes and Their Potential Role in Breast Cancer Cancer Res., September 1, 2000; 60(17): 4667 - 4677. [Abstract] [Full Text] |
||||
![]() |
S. A. Wardlaw, T. H. March, and S. A. Belinsky Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions Carcinogenesis, July 1, 2000; 21(7): 1371 - 1377. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Komhoff, Y. Guan, H. W. Shappell, L. Davis, G. Jack, Y. Shyr, M. O. Koch, S. B. Shappell, and M. D. Breyer Enhanced Expression of Cyclooxygenase-2 in High Grade Human Transitional Cell Bladder Carcinomas Am. J. Pathol., July 1, 2000; 157(1): 29 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
M J S Langman, K K Cheng, E A Gilman, and R J Lancashire Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database BMJ, June 17, 2000; 320(7250): 1642 - 1646. [Abstract] [Full Text] |
||||
![]() |
A.-L. Hsu, T.-T. Ching, D.-S. Wang, X. Song, V. M. Rangnekar, and C.-S. Chen The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2 J. Biol. Chem., April 6, 2000; 275(15): 11397 - 11403. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Bauer, L. D. Dwyer-Nield, and A. M. Malkinson High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors Carcinogenesis, April 1, 2000; 21(4): 543 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Shamma, H. Yamamoto, Y. Doki, J. Okami, M. Kondo, Y. Fujiwara, M. Yano, M. Inoue, N. Matsuura, H. Shiozaki, et al. Up-Regulation of Cyclooxygenase-2 in Squamous Carcinogenesis of the Esophagus Clin. Cancer Res., April 1, 2000; 6(4): 1229 - 1238. [Abstract] [Full Text] |
||||
![]() |
K. Uefuji, T. Ichikura, and H. Mochizuki Cyclooxygenase-2 Expression Is Related to Prostaglandin Biosynthesis and Angiogenesis in Human Gastric Cancer Clin. Cancer Res., January 1, 2000; 6(1): 135 - 138. [Abstract] [Full Text] |
||||
![]() |
A. J. Trimboli, B. M. Waite, G.-i. Atsumi, A. N. Fonteh, A. M. Namen, C. E. Clay, T. E. Kute, K. P. High, M. C. Willingham, and F. H. Chilton Influence of Coenzyme A-independent Transacylase and Cyclooxygenase Inhibitors on the Proliferation of Breast Cancer Cells Cancer Res., December 1, 1999; 59(24): 6171 - 6177. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kondo, H. Yamamoto, H. Nagano, J. Okami, Y. Ito, J. Shimizu, H. Eguchi, A. Miyamoto, K. Dono, K. Umeshita, et al. Increased Expression of COX-2 in Nontumor Liver Tissue Is Associated with Shorter Disease-free Survival in Patients with Hepatocellular Carcinoma Clin. Cancer Res., December 1, 1999; 5(12): 4005 - 4012. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. Mohammed, D. W. Knapp, D. G. Bostwick, R. S. Foster, K. N. M. Khan, J. L. Masferrer, B. M. Woerner, P. W. Snyder, and A. T. Koki Expression of Cyclooxygenase-2 (COX-2) in Human Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder Cancer Res., November 1, 1999; 59(22): 5647 - 5650. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Tremblay, M. Dore, P. N. Bochsler, and J. Sirois Induction of Prostaglandin G/H Synthase-2 in a Canine Model of Spontaneous Prostatic Adenocarcinoma J Natl Cancer Inst, August 18, 1999; 91(16): 1398 - 1403. [Abstract] [Full Text] [PDF] |
||||



































